Devicor completes acquisition of Ethicon Endo-Surgery's Breast Care business

NewsGuard 100/100 Score

Devicor Medical Products, Inc. (Devicor), a portfolio company of GTCR, announced today that the company has completed the acquisition of Ethicon Endo-Surgery's (EES) Breast Care business. The Breast Care business sells products designed to help doctors diagnose breast cancer at early stages while minimizing patient discomfort. The business will formally be known as Mammotome, a division of Devicor Medical Products, Inc.

The EES Breast Care product portfolio is sold in 50 countries around the world and includes the Mammotome® Breast Biopsy System and tissue markers (MammoMARK®, MicroMARK®, and CorMARK®) used for breast disease diagnostic sampling and management. As part of the agreement, Devicor also acquired marketing and distribution rights for Neoprobe® Gamma Detection Systems.

"Mammotome is a global leader in vacuum assisted breast biopsy devices and is a brand that is recognized worldwide. Today, we are excited to begin the work of further developing the Mammotome brand globally," says Tom Daulton, Chief Executive Officer, Devicor and Mammotome.

Mammotome's corporate headquarters will be located in Sharonville, Ohio, where it has leased 30,000 square feet of office space in Summit Woods Office Park, at 300 E-BusinessWay. Recently, the company was awarded a 60 percent job creation tax credit for seven years, valued at $1.5 million, from the Ohio Department of Development.

Now that the transaction is complete, nearly 300 EES associates primarily dedicated to the Breast Care business will be hired by Mammotome. "The talent and expertise of the Mammotome employees will allow us to continue to provide the best in innovative technologies to our customers around the world," says Daulton.

Mammotome's plans for growth include adding more than 150 jobs worldwide of which approximately 70 positions will be located at the corporate headquarters. In addition, Mammotome plans to build a new manufacturing plant in the next 12-18 months.

"The acquisition of the Breast Care business is a key component in achieving our objective of building a leading medical device business," says Dean Mihas, Principal of GTCR. "Given Tom Daulton's impressive track record leading and growing global medical device businesses, we're excited to be a partner in this acquisition and are committed to providing the resources to further strengthen Mammotome's market leading position through organic growth and strategic expansion."

Source:

Devicor Medical Products, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Smoking, drinking, and dietary habits linked to head and neck cancer risk, study finds